Conditions: Metabolic Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 46
Healthy volunteers: yes

Brief summary:
Test the hypothesis that nebivolol treatment improves fibrinolytic balance and insulin sensitivity compared to metoprolol treatment in individuals with metabolic syndrome.

Detailed description:
1. Test the hypothesis that nebivolol treatment decreases PAI-1 antigen and activity and improves fibrinolytic balance compared to metoprolol treatment in individuals with metabolic syndrome.
2. Test the hypothesis that nebivolol treatment improves insulin sensitivity compared to metoprolol treatment in individuals with metabolic syndrome.

Arms:
arm 1: Nebivolol 5mg by mouth daily for 12 weeks. arm 2: Metoprolol ER 100mg by mouth daily for 12 weeks.

Interventions: intervention 1: placebo intervention 2: Nebivolol intervention 3: Metoprolol
Intervention descriptions: intervention 1: Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks. intervention 2: Nebivolol 5 mg by mouth daily for 12 weeks. intervention 3: Metoprolol ER 100mg by mouth daily for 12 weeks.

Protocol document: